By analyzing existing basic indicators between Acer Therapeutics and DYADIC, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in DYADIC with a short position in Acer Therapeutics. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Acer Therapeutics has an asset utilization ratio of 9.09 percent. This connotes that the company is making $0.0909 for each dollar of assets. An increasing asset utilization means that Acer Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two entities, such as Acer or SAB is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.
How important is Acer Therapeutics's Liquidity
Acer Therapeutics
financial leverage refers to using borrowed capital as a funding source to finance Acer Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Acer Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Acer Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Acer Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Acer Therapeutics's total debt and its cash.
Correlation Between Acer and SAB Biotherapeutics
In general, Delisted Stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Acer Therapeutics together with similar or unrelated positions with a negative correlation. For example, you can also add SAB Biotherapeutics to your portfolio. If SAB Biotherapeutics is not perfectly correlated to Acer Therapeutics it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Acer Therapeutics, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Are you currently holding both Acer Therapeutics and SAB Biotherapeutics in your portfolio? Please note if you are using this as a pair-trade strategy between Acer Therapeutics and SAB Biotherapeutics, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses. Please check
pair correlation details between ACER and SABS for more information.
What is driving Acer Therapeutics Investor Appetite?
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Revenue Breakdown
Lets now take a look at Acer Therapeutics revenue. Based on the latest financial disclosure, Acer Therapeutics reported 1.75
M of revenue. This is 99.98% lower than that of the Healthcare sector and 99.76% lower than that of the
Biotechnology industry. The revenue for all United States stocks is 99.98% higher than that of the firm. As for DYADIC INTERNATIONAL we see revenue of 1.69
M, which is 99.77% lower than that of the Biotechnology
| ACER | 1.75 Million | 0.23 |
| Sector | 742.91 Million | 99.54 |
| DYAI | 1.69 Million | 0.23 |
Another 3 percent spike for Acer Therapeutics
Sortino ratio is down to 0.14. It may connote a possible volatility fall. As of the 17th of January 2021, Acer Therapeutics shows the
risk adjusted performance of 0.1099, and Mean Deviation of 3.18. Acer Therapeutics
technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen
technical drivers for Acer Therapeutics, which can be compared to its rivals. Please confirm
Acer Therapeutics jensen alpha, and the
relationship between the
coefficient of variation and
potential upside to decide if Acer Therapeutics is priced correctly, providing market reflects its regular price of 3.85 per share. Given that Acer Therapeutics has
jensen alpha of 0.506, we suggest you to validate Acer Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.
While some firms under the biotechnology industry are still a bit expensive, Acer Therapeutics may offer a potential longer-term growth to retail investors. To conclude, as of the 17th of January 2021, we see that Acer Therapeutics slowly supersedes the market. The enterprise is
undervalued with
very small chance of financial distress within the next 24 months. Our present 30 days buy vs. sell advice on the enterprise is
Strong Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Acer Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
